Saroj Niraula
Overview
Explore the profile of Saroj Niraula including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1080
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rittberg R, Czaykowski P, Niraula S
JNCI Cancer Spectr
. 2021 Aug;
5(4).
PMID: 34409254
Background: The US Food and Drug Administration (FDA) introduced an Accelerated Approval (AA) pathway to expedite patient access to new drugs. AA accepts less rigorous trial designs, including single-arm studies...
2.
Gyawali B, Niraula S
J Natl Compr Canc Netw
. 2020 Nov;
18(11):1441-1444.
PMID: 33152697
No abstract available.
3.
Niraula S, Biswanger N, Hu P, Lambert P, Decker K
JAMA Netw Open
. 2020 Sep;
3(9):e2018179.
PMID: 32975573
Importance: Breast cancer comprises a highly heterogeneous group of diseases. Many breast cancers, particularly the more lethal ones, may not satisfy the assumptions about biology and natural history of breast...
4.
Oberoi S, Yang J, Woodgate R, Niraula S, Banerji S, Israels S, et al.
JAMA Netw Open
. 2020 Aug;
3(8):e2012598.
PMID: 32766801
Importance: Mindfulness-based interventions (MBIs), grounded in mindfulness, focus on purposely paying attention to experiences occurring at the present moment without judgment. MBIs are increasingly used by patients with cancer for...
5.
Geirnaert M, Howarth J, Kellett C, Martin K, Streilein S, Ricard C, et al.
J Oncol Pharm Pract
. 2020 Jul;
26(7):1683-1685.
PMID: 32727322
The product monograph for reference bevacizumab (Avastin) and biosimilar bevacizumab (Mvasi) recommend to infuse the first dose of bevacizumab over 90 min, second dose over 60 min and third and...
6.
Asselin C, Lam A, Cheung D, Eekhoudt C, Zhu A, Mittal I, et al.
J Nutr
. 2020 Jun;
150(9):2353-2363.
PMID: 32510147
Background: Although the combination of doxorubicin (DOX) and trastuzumab (TRZ) reduces the progression and recurrence of breast cancer, these anticancer drugs are associated with significant cardiotoxic side effects. Objective: We...
7.
8.
Leslie W, Morin S, Lix L, Niraula S, McCloskey E, Johansson H, et al.
Oncologist
. 2019 Jul;
24(11):1432-1438.
PMID: 31292269
Background: Aromatase inhibitors (AIs) used in breast cancer induce loss in bone mineral density (BMD) and are reported to increase fracture risk. Materials And Methods: Using a population-based BMD registry,...
9.
Niraula S
Cancer
. 2019 Jun;
125(18):3100-3103.
PMID: 31154671
A universal health care system has been a source of both identity and pride for Canadians for the last 6 decades. Currently, Canada actively negotiates the prices of cancer drugs...
10.
Leslie W, Morin S, Lix L, Niraula S, McCloskey E, Johansson H, et al.
J Bone Miner Res
. 2019 May;
34(8):1428-1435.
PMID: 31069862
FRAX was developed to predict 10-year probability of major osteoporotic fracture (MOF) and hip fracture in the general population. Aromatase inhibitors (AI) used in breast cancer induce loss in bone...